PARTNERTM药物洗脱支架临床应用.docVIP

PARTNERTM药物洗脱支架临床应用[摘要]目的：评价PARTNERTM药物洗脱支架的临床疗效及安全性。方法：选择2006年1~12月111例冠心病患者，所有患者行经皮冠状动脉介入治疗置入PARTNERTM药物洗脱支架，术后对患者进行随访，观察有无胸痛复发、心电图改变及重要心血管不良事件的发生。结果：111例患者共180处病变置入196枚PARTNERTM药物洗脱支架，手术成功率100%，胸痛缓解无复发，术后无重要心血管不良事件发生。结论：PCI术中应用国产PARTNERTM雷帕霉素药物洗脱支架近期疗效满意，应用安全方便。 [关键词]血管成形术；经腔；经皮冠状动脉；支架；雷帕霉素；再狭窄 [中图分类号]R541[文献标识码]B [文章编号]1673-7210（2007）09（c）-032-02 The clinical application of PARTNERTM drug-eluting stent in patients with coronary artery disease HUANG Bin，LI Xin，BAI Jing，QIN Long-fei，SHEN Hang (Department of Interventional, the Fifth Affiliated Hospital of Zhengzhou Medical University, Zhengzhou 450052,China) [Abstract]Objective：To evaluate the safety and effectiveness of PARTNERTM stent in clinical application.Methods：From Jan 2006 to Dec 2006,111 patients were treated with PARTNERTM drug-eluting stent. Clinical follow-up was conducted in all these patients for major adverse cardiac events such as angina pectoris,myocardial infarction,sudden death and revascularization. Results：196 PARTNERTM drug-eluting stent were implanted to 180 coronary artery lesions in all these patients.The immediate procedure success rate of stent implantation was 100%.There were no angina pectoris and no major adverse cardiac events. Conclusion：Short-term clinical follow-up shows PARTNERTM drug-eluting stent is safe and effective in treatment of coronary artery disease. [Key words]Angioplasty；Transluminal；Percutaneous coaonary；Stent；Rapamycin；Restenosis 经皮冠状动脉介入治疗（percutaneous coronary intervention,PCI）中药物洗脱支架的应用已经成为继单纯球囊扩张术、支架置入术之后，介入心脏病学发展史上的第三个里程碑[1]。目前国内外大规模临床试验已证实携带雷帕霉素的CypherTM支架可以明显降低PCI术的再狭窄发生率[2~4]。国产的PARTNERTM雷帕霉素药物洗脱支架（北京乐普医疗器械有限公司）临床使用时间较短，目前关于其临床疗效的报道较少。本研究探讨PARTNERTM药物洗脱支架的临床疗效及安全性。 1 对象与方法 1．1 对象 选择PARTNERTM药物洗脱支架2005年11月上市以来于我院2006年1~12月行PCI术置入PARTNERTM支架的冠心病患者111例，其中男性102例，女性9例，平均年龄(62.0±12.3)岁；其中稳定型心绞痛18例(16.2%)，不稳定型心绞痛57例(51.4%)，心肌梗死36例(32.4%)；其中合并高血压病78例(70.3%)，合并糖尿病21例(18.9%)，合并高脂血症81例(73.0%)，合并吸烟60例(54.1%)。 1．2 方法 1．2．1 术前准备所有患者